KRAS Cancer News & Updates

Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...

A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...

" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...

PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...

Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024   “ Brief Summary This is a...

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)   Phase 1/2 - 403 patients to enroll Opened in...

"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),...

Phase 1 trial  Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors Enrollment into...

"Brief Summary Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as...

“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in...